Co-Authors
This is a "connection" page, showing publications co-authored by JENNIFER WARGO and MICHAEL WHITE.
Connection Strength
3.613
-
The Microbiome in Gastrointestinal Cancers. Gastroenterol Clin North Am. 2022 09; 51(3):667-680.
Score: 0.880
-
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
Score: 0.832
-
Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 09 17; 79(6):878-880.
Score: 0.769
-
Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy. Ann Surg. 2023 10 01; 278(4):538-548.
Score: 0.234
-
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
Score: 0.225
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.210
-
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).
Score: 0.207
-
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017 08; 7(8):832-851.
Score: 0.152
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.054
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.051